PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE: A
PRACTICAL APPROACH, 5TH EDITION ARCANGELO –
COMPREHENSIVE TEST BANK (2025/2026 ULTIMATE GUIDE)
SECTION 1: ISSUES FOR THE PRACTITIONER & PRESCRIPTIVE AUTHORITY
1. Nurse practitioner prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Answer: C) The State Board of Nursing for each state
Rationale: Prescriptive authority for NPs is regulated at the state level by each state's Board
of Nursing, leading to state-by-state variation in practice. The DEA regulates controlled
substances at the federal level but does not grant prescriptive authority. The National
Council of State Boards of Nursing is an advisory body, not a regulatory one.
2. Physician Assistant prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing
D) The State Board of Medical Examiners
Answer: D) The State Board of Medical Examiners
Rationale: PA prescriptive authority is regulated by the State Board of Medical Examiners
because PAs practice under physician supervision.
, 3. Clinical judgment in prescribing includes:
A) Factoring in the cost to the patient of the medication prescribed
B) Always prescribing the newest medication available for the disease process
C) Handing out drug samples to poor patients
D) Prescribing all generic medications to cut costs
Answer: A) Factoring in the cost to the patient of the medication prescribed
Rationale: Clinical judgment involves considering the patient's financial ability to afford
medications. Nonadherence is common when patients cannot afford their prescriptions.
The newest drug is not always best; drug samples should not be indiscriminate; generics
are preferred but not always appropriate for narrow therapeutic index drugs.
4. Criteria for choosing an effective drug for a disorder include:
A) Asking the patient what drug they think would work best for them
B) Consulting nationally recognized guidelines for disease management
C) Prescribing medications that are available as samples before writing a
prescription
D) Following U.S. Drug Enforcement Administration guidelines for prescribing
Answer: B) Consulting nationally recognized guidelines for disease management
Rationale: Nationally recognized guidelines provide evidence-based recommendations for
disease management. Patient preferences should be considered but are not the sole
criterion. Drug samples should not dictate prescribing choices.
5. Nurse practitioner practice may thrive under health-care reform due to:
A) The demonstrated ability of nurse practitioners to control costs and improve
patient outcomes
B) The fact that nurse practitioners will be able to practice independently
C) The fact that nurse practitioners will have full reimbursement under health-care
reform
D) The ability to shift accountability for Medicaid to the state level
Answer: A) The demonstrated ability of nurse practitioners to control costs and
improve patient outcomes
Rationale: NPs have demonstrated ability to control costs and improve patient outcomes,
which positions them well under healthcare reform models that emphasize value-based
care.
6. The provider's responsibilities regarding a "Pain Medication Contract" include:
A) Using it universally for all prescribing for chronic pain
, B) Using it for patients who have repeated requests for pain medication
C) Using it when you suspect a patient is exhibiting drug-seeking behavior
D) Using it for patients with pain associated with malignancy
Answer: A) Using it universally for all prescribing for chronic pain
Rationale: Pain medication agreements are recommended universally for all patients
receiving chronic opioid therapy, not only those with suspected aberrant behavior. They
establish mutual expectations, monitoring requirements, and risks/benefits.
7. A patient asks the APRN why their medication needs to be taken with food. The
APRN explains that food can affect:
A) Drug potency
B) Drug bioavailability
C) Drug efficacy
D) Drug safety
Answer: B) Drug bioavailability
Rationale: Food can affect drug bioavailability by altering absorption. Some drugs require
food to enhance absorption, while others should be taken on an empty stomach to avoid
reduced absorption.
8. The APRN is reviewing a patient's medication list and notes that a drug has a narrow
therapeutic index. This means:
A) The drug has a wide margin of safety
B) The drug requires careful monitoring to prevent toxicity
C) The drug is safe at a wide range of doses
D) The drug does not require blood level monitoring
Answer: B) The drug requires careful monitoring to prevent toxicity
Rationale: Narrow therapeutic index drugs have a small difference between effective and
toxic doses, requiring careful dosing and monitoring (e.g., warfarin, digoxin, phenytoin,
lithium).
9. The APRN understands that pharmacotherapeutics is defined as:
A) The study of drug cost
B) The use of drugs to treat disease
C) Drug marketing strategies
D) Drug manufacturing processes
Answer: B) The use of drugs to treat disease
, Rationale: Pharmacotherapeutics is the branch of pharmacology concerned with the use
of drugs to treat disease.
10. A drug with a high first-pass effect will have:
A) High oral bioavailability
B) Rapid metabolism by the liver before reaching systemic circulation
C) Primarily renal excretion
D) Long duration of action
Answer: B) Rapid metabolism by the liver before reaching systemic circulation
Rationale: First-pass effect refers to the rapid metabolism of a drug by the liver before it
reaches systemic circulation, reducing oral bioavailability.
11. The APRN is explaining to a patient why a generic medication may be preferred.
Which statement is accurate?
A) Generics are always identical to brand-name drugs
B) Generics may have different inactive ingredients but the same active ingredient
C) Generics are always less effective than brand-name drugs
D) Generics are not regulated by the FDA
Answer: B) Generics may have different inactive ingredients but the same active
ingredient
Rationale: Generic medications contain the same active ingredient but may have different
inactive ingredients (fillers, binders, dyes). They are FDA-approved and must demonstrate
bioequivalence.
12. The APRN is reviewing a new prescription for a patient. Which of the following is an
example of off-label prescribing?
A) Prescribing a medication for a condition not approved by the FDA
B) Prescribing a medication at a dose lower than the recommended dose
C) Prescribing a medication for a patient younger than the approved age
D) Prescribing a medication that is not covered by the patient's insurance
Answer: A) Prescribing a medication for a condition not approved by the FDA
Rationale: Off-label prescribing refers to using an FDA-approved medication for a
condition, population, or dose not specifically approved by the FDA.
13. The APRN understands that the primary purpose of the Drug Enforcement
Administration (DEA) is to:
A) Approve new medications for marketing
PRACTICAL APPROACH, 5TH EDITION ARCANGELO –
COMPREHENSIVE TEST BANK (2025/2026 ULTIMATE GUIDE)
SECTION 1: ISSUES FOR THE PRACTITIONER & PRESCRIPTIVE AUTHORITY
1. Nurse practitioner prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Answer: C) The State Board of Nursing for each state
Rationale: Prescriptive authority for NPs is regulated at the state level by each state's Board
of Nursing, leading to state-by-state variation in practice. The DEA regulates controlled
substances at the federal level but does not grant prescriptive authority. The National
Council of State Boards of Nursing is an advisory body, not a regulatory one.
2. Physician Assistant prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing
D) The State Board of Medical Examiners
Answer: D) The State Board of Medical Examiners
Rationale: PA prescriptive authority is regulated by the State Board of Medical Examiners
because PAs practice under physician supervision.
, 3. Clinical judgment in prescribing includes:
A) Factoring in the cost to the patient of the medication prescribed
B) Always prescribing the newest medication available for the disease process
C) Handing out drug samples to poor patients
D) Prescribing all generic medications to cut costs
Answer: A) Factoring in the cost to the patient of the medication prescribed
Rationale: Clinical judgment involves considering the patient's financial ability to afford
medications. Nonadherence is common when patients cannot afford their prescriptions.
The newest drug is not always best; drug samples should not be indiscriminate; generics
are preferred but not always appropriate for narrow therapeutic index drugs.
4. Criteria for choosing an effective drug for a disorder include:
A) Asking the patient what drug they think would work best for them
B) Consulting nationally recognized guidelines for disease management
C) Prescribing medications that are available as samples before writing a
prescription
D) Following U.S. Drug Enforcement Administration guidelines for prescribing
Answer: B) Consulting nationally recognized guidelines for disease management
Rationale: Nationally recognized guidelines provide evidence-based recommendations for
disease management. Patient preferences should be considered but are not the sole
criterion. Drug samples should not dictate prescribing choices.
5. Nurse practitioner practice may thrive under health-care reform due to:
A) The demonstrated ability of nurse practitioners to control costs and improve
patient outcomes
B) The fact that nurse practitioners will be able to practice independently
C) The fact that nurse practitioners will have full reimbursement under health-care
reform
D) The ability to shift accountability for Medicaid to the state level
Answer: A) The demonstrated ability of nurse practitioners to control costs and
improve patient outcomes
Rationale: NPs have demonstrated ability to control costs and improve patient outcomes,
which positions them well under healthcare reform models that emphasize value-based
care.
6. The provider's responsibilities regarding a "Pain Medication Contract" include:
A) Using it universally for all prescribing for chronic pain
, B) Using it for patients who have repeated requests for pain medication
C) Using it when you suspect a patient is exhibiting drug-seeking behavior
D) Using it for patients with pain associated with malignancy
Answer: A) Using it universally for all prescribing for chronic pain
Rationale: Pain medication agreements are recommended universally for all patients
receiving chronic opioid therapy, not only those with suspected aberrant behavior. They
establish mutual expectations, monitoring requirements, and risks/benefits.
7. A patient asks the APRN why their medication needs to be taken with food. The
APRN explains that food can affect:
A) Drug potency
B) Drug bioavailability
C) Drug efficacy
D) Drug safety
Answer: B) Drug bioavailability
Rationale: Food can affect drug bioavailability by altering absorption. Some drugs require
food to enhance absorption, while others should be taken on an empty stomach to avoid
reduced absorption.
8. The APRN is reviewing a patient's medication list and notes that a drug has a narrow
therapeutic index. This means:
A) The drug has a wide margin of safety
B) The drug requires careful monitoring to prevent toxicity
C) The drug is safe at a wide range of doses
D) The drug does not require blood level monitoring
Answer: B) The drug requires careful monitoring to prevent toxicity
Rationale: Narrow therapeutic index drugs have a small difference between effective and
toxic doses, requiring careful dosing and monitoring (e.g., warfarin, digoxin, phenytoin,
lithium).
9. The APRN understands that pharmacotherapeutics is defined as:
A) The study of drug cost
B) The use of drugs to treat disease
C) Drug marketing strategies
D) Drug manufacturing processes
Answer: B) The use of drugs to treat disease
, Rationale: Pharmacotherapeutics is the branch of pharmacology concerned with the use
of drugs to treat disease.
10. A drug with a high first-pass effect will have:
A) High oral bioavailability
B) Rapid metabolism by the liver before reaching systemic circulation
C) Primarily renal excretion
D) Long duration of action
Answer: B) Rapid metabolism by the liver before reaching systemic circulation
Rationale: First-pass effect refers to the rapid metabolism of a drug by the liver before it
reaches systemic circulation, reducing oral bioavailability.
11. The APRN is explaining to a patient why a generic medication may be preferred.
Which statement is accurate?
A) Generics are always identical to brand-name drugs
B) Generics may have different inactive ingredients but the same active ingredient
C) Generics are always less effective than brand-name drugs
D) Generics are not regulated by the FDA
Answer: B) Generics may have different inactive ingredients but the same active
ingredient
Rationale: Generic medications contain the same active ingredient but may have different
inactive ingredients (fillers, binders, dyes). They are FDA-approved and must demonstrate
bioequivalence.
12. The APRN is reviewing a new prescription for a patient. Which of the following is an
example of off-label prescribing?
A) Prescribing a medication for a condition not approved by the FDA
B) Prescribing a medication at a dose lower than the recommended dose
C) Prescribing a medication for a patient younger than the approved age
D) Prescribing a medication that is not covered by the patient's insurance
Answer: A) Prescribing a medication for a condition not approved by the FDA
Rationale: Off-label prescribing refers to using an FDA-approved medication for a
condition, population, or dose not specifically approved by the FDA.
13. The APRN understands that the primary purpose of the Drug Enforcement
Administration (DEA) is to:
A) Approve new medications for marketing
